BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

870 related articles for article (PubMed ID: 26768987)

  • 21. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.
    Buckley RH; Schiff SE; Schiff RI; Markert L; Williams LW; Roberts JL; Myers LA; Ward FE
    N Engl J Med; 1999 Feb; 340(7):508-16. PubMed ID: 10021471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency.
    Wahlstrom J; Patel K; Eckhert E; Kong D; Horn B; Cowan MJ; Dvorak CC
    J Allergy Clin Immunol; 2017 Feb; 139(2):628-633.e10. PubMed ID: 27444177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of TCR α
    Brettig T; Smart J; Choo S; Mechinaud F; Mitchell R; Raj TS; Cole T
    J Clin Immunol; 2019 Jul; 39(5):505-511. PubMed ID: 31172381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.
    Gilman AL; Leung W; Cowan MJ; Cannon M; Epstein S; Barnhart C; Shah K; Hyland M; Fukes T; Ivanova A
    Am J Hematol; 2018 Feb; 93(2):169-178. PubMed ID: 29047161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.
    Koh LP; Rizzieri DA; Chao NJ
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1249-67. PubMed ID: 17950913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
    Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
    J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
    Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
    Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders.
    Knutsen AP; Wall DA
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):823-32. PubMed ID: 10329816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease.
    Scheiermann J; Künkele A; von Stackelberg A; Eggert A; Lang P; Zirngibl F; Martin L; Schulte JH; von Bernuth H
    Front Immunol; 2023; 14():1042650. PubMed ID: 36875143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).
    Dickinson AM; Reid MM; Abinun M; Peak J; Brigham K; Dunn J; Cant AJ
    Bone Marrow Transplant; 1997 Feb; 19(4):323-9. PubMed ID: 9051241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
    Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
    Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis.
    Roy DC; Lachance S; Cohen S; Delisle JS; Kiss T; Sauvageau G; Busque L; Ahmad I; Bernard L; Bambace N; Boumédine RS; Guertin MC; Rezvani K; Mielke S; Perreault C; Roy J
    Br J Haematol; 2019 Sep; 186(5):754-766. PubMed ID: 31135970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
    Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A
    Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
    Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
    Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
    Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD3
    Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
    Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.
    Meyer RG; Britten CM; Wehler D; Bender K; Hess G; Konur A; Hartwig UF; Wehler TC; Ullmann AJ; Gentilini C; Uharek L; Huber C; Kolbe K; Herr W
    Blood; 2007 Jan; 109(1):374-82. PubMed ID: 16940425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.